The company have significantly improved its progress of a new treatment for amyloid heart disease, leveraging the investigational drug. Preliminary trial data reveals potential improvements for patients affected by this severe disease. The emphasis underscores BridgeBio's dedication to treating unmet medical demands in the heart field. … Read More